AV-101 (4-Cl-KYN)

AV-101 (L-4-chlorokyurenine or 4-CI-KYN) is an orally-available new generation prodrug candidate for Major Depressive Disorder and other diseases and disorders involving the central nervous system (CNS), including chronic neuropathic pain, epilepsy and neurodegenerative diseases, such as Parkinson’s disease and Huntington’s disease. After crossing the blood-brain barrier and reaching brain astrocytes, AV-101 is rapidly and enzymatically converted into 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized, potent and selective antagonist of N-methyl-D-aspartate (NMDA) receptors, acting by blocking the glycine-binding co-agonist site within the NMDA receptor.